Trial · NCT07903636
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07903636, Phase 2, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease. Trials, record NCT07903636. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07903636
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
- NCT number
- NCT07903636
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 55 participants, estimated
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Conditions
- Multiple Myeloma (MM)
- Interventions
- QLS4131
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Response Rate (ORR) | From the first dose to the end of Cycle 24 (each cycle is 28 days). | |
| Secondary | Extramedullary Disease Objective Response Rate (EMD-ORR) | From the first dose to the end of Cycle 24 (each cycle is 28 days). | |
| Secondary | Very Good Partial Response or Better Rate (≥VGPR Rate) | From the first dose to the end of Cycle 24 (each cycle is 28 days). | |
| Secondary | Complete Response or Stringent Complete Response Rate (CR/sCR Rate) | From the first dose to the end of Cycle 24 (each cycle is 28 days). | |
| Secondary | Time to Response (TTR) | From the first dose to the date of the first documented overall response of PR or better, assessed through the end of Cycle 24 (each cycle is 28 days). | |
| Secondary | Duration of Response (DoR) | From the date of the first documented overall response of PR or better to the date of disease progression or death from any cause, whichever occurs first, with follow-up through 12 months after the last dose. | |
| Secondary | Progression-Free Survival (PFS) | From the date of the first dose to the date of disease progression or death from any cause, whichever occurs first, with follow-up through 12 months after the last dose. | |
| Secondary | Overall Survival (OS) | From the date of the first dose to the date of death from any cause, with follow-up through 12 months after the last dose. | |
| Secondary | Incidence and Severity of Adverse Events (AEs) | Up to 2 years. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07903636
GET https://conductscience.org/api/trials/v1/NCT07903636/registered